NSCLC: COPD tied to better PFS, OS with pembrolizumab

  • Shin SH & al.
  • Int J Cancer
  • 26 Feb 2019

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with NSCLC and coexisting COPD who received palliative pembrolizumab had better OS, PFS, and objective response rates (ORR) than patients without COPD.

Why this matters

  • Previous studies suggesting an association between coexisting COPD and longer PFS with immune checkpoint inhibitors in NSCLC used a clinical diagnosis of COPD or spirometry-defined COPD in

Study design

  • 133 patients with lung cancer who received palliative pembrolizumab between July 2014 and January 2018 who had undergone spirometry testing for COPD within the past 3 years.
  • Funding: Ministry of Trade, Industry, and Energy; others.

Key results

  • 44% had COPD.
  • Coexisting COPD was associated with better OS (aHR for death, 0.51; 95% CI, 0.28-0.90) and PFS (aHR for disease progression or death, 0.61; 95% CI, 0.37-0.99).
  • ORR was higher in patients with vs without COPD (38.2% vs 20.5%; P=.028).
  • Compared with patients with moderate or severe COPD, those with mild COPD had better OS (aHR for death, 0.27; 95% CI, 0.09-0.78) and PFS (aHR for disease progression or death, 0.21; 95% CI, 0.06-0.70).

Limitations

  • Retrospective, single-center study.